Containing Ebola: Fear, Caregiving, and Outbreak Response

Summary

In May 2026, a new outbreak of Bundibugyo Ebola virus disease emerged in the Democratic Republic of the Congo and Uganda, prompting WHO to declare a Public Health Emergency of International Concern. But beyond the alarming headlines and familiar imagery lies a more complicated reality.

In this episode of Infectious Dose, we examine what Ebola actually is, how it spreads, what it does inside the body, and why outbreaks continue to emerge decades after the virus was first identified in 1976. We explore the biology of Ebola, the history of outbreaks from Yambuku to Kikwit to West Africa, the role of healthcare amplification and caregiving in transmission, and how fear has shaped public understanding of the disease.

We also discuss the current 2026 Bundibugyo outbreak, the challenges posed by delayed recognition and strained healthcare systems, and what modern outbreak response tools — including vaccines, monoclonal antibodies, and genomic surveillance — can and cannot do.

Along the way, we tackle listener questions about airborne transmission, why Ebola keeps returning, whether mosquitoes or pets can spread Ebola, and what outbreaks like this reveal about public health infrastructure, trust, and global preparedness.

This episode contains discussion of severe illness and death.

Listen here or scroll down to read full episode.

Full Episode

Any linked citations that are paywalled, are provided as PDFs in citation list at end of post.

Jeanne

In March 2021, in eastern Democratic Republic of the Congo, a woman named Jeanne sat awake through the night listening to her husband struggle to breathe. At first, she tried to convince herself it wasn’t Ebola. Fever was common. Severe illness was common. In another year, another village, it might have been malaria. Typhoid. Cholera. Something survivable. But this was North Kivu. And only days earlier, health officials had announced that Ebola had returned.

By morning, Jeanne brought her husband to an Ebola treatment center. Blood tests confirmed what she already feared: he was infected. Then she tested positive too. So did her mother-in-law.

Inside the treatment center, families were separated into different rooms. Protective equipment concealed faces. Conversations happened through layers of plastic, masks, and distance. Within days, Jeanne’s husband died. Then her mother-in-law died too. She was not allowed to sit beside them the way families normally would. Not allowed to touch them. Not allowed to grieve in the ways grief usually asks us to grieve. And while she was still trying to process their deaths, she herself was fighting the same virus that had killed them.

Weeks later, Jeanne survived. But survival did not return her old life. Some family members rejected her. Neighbors feared her. The outbreak eventually faded from international headlines, but for survivors, Ebola rarely ends when the virus leaves the bloodstream. Because Ebola is not only a story about hemorrhage and containment. It is a story about what fear does to hospitals. To families. To communities. And to the people left alive afterward.

This is Containing Ebola: Fear, Caregiving, and Outbreak Response

Ebola occupies a strange place in the public imagination. For decades, it has existed as both a real virus and a kind of cultural shorthand for catastrophe. The name alone evokes hazmat suits, hemorrhage, quarantine tape, and societal collapse. Few pathogens became so symbolically powerful, especially in places far removed from the outbreaks themselves.

Part of that fear came from the numbers. Some Ebola outbreaks caused mortality rates that were almost difficult to comprehend. Part came from the visuals — healthcare workers in full protective equipment, treatment units sealed behind plastic barriers, entire communities transformed by infection control measures and fear. And part came from timing. Ebola made a devastating re-emergence in 2014—in the West African epidemic that infected almost 30,000 people—during an era of expanding global media, when terrifying images could move around the world almost instantly, long before most people understood the biology behind what they were seeing.

But the mythology of Ebola has always been somewhat different from the reality. The real story is not a virus that spreads effortlessly through the air, tearing indiscriminately across populations like something out of an apocalyptic film. In fact, one of the most important things about Ebola is that it generally does not spread efficiently through casual everyday interaction....more on that in a minute.

And yet outbreaks still became devastating. That contradiction is where the real story begins. Because Ebola spreads through caregiving. Through hospitals operating under strain. Through delayed recognition. Through reused equipment, exhausted healthcare workers, family members trying to keep loved ones alive, and communities navigating fear with limited information and resources.

Now, as Bundibugyo Ebola is again in the headlines, the question isn’t just what Ebola is. It’s why this virus keeps finding the cracks in human systems. This episode dives into that. We’re going to talk about what Ebola is, what it does inside the body, what's happening with the current outbreak, and why outbreaks keep happening. And the real biology of Ebola is both less cinematic and, in many ways, more revealing than the mythology that grew around it. To understand how that mythology formed, we have to go back to the beginning. To 1976.

PART I — 1976

In 1976, before most of the world had ever heard the word “Ebola,” two outbreaks began unfolding almost simultaneously in Central Africa. At first, they did not appear connected. One outbreak emerged in what is now South Sudan, centered around the town of Nzara. The other appeared hundreds of miles away in what was then Zaire, now the Democratic Republic of the Congo. Both began with fever. And both initially looked like countless other illnesses that healthcare workers in the region were already used to seeing.

That’s one of the recurring realities of emerging infectious diseases: in the beginning, they rarely announce themselves dramatically. They hide inside symptoms that overlap with diseases clinicians already encounter every day. Like malaria. Typhoid. Dysentery. Severe bacterial infections. Fever alone does not reveal that something historically significant is happening.

But over time, patterns began to emerge that were difficult to ignore. Patients deteriorated rapidly. Clusters of illness appeared around hospitals and caregiving settings. Healthcare workers themselves began getting sick. And mortality was extraordinarily high.

The outbreak in Zaire eventually centered around a Catholic mission hospital in the village of Yambuku. That hospital would become one of the defining early examples of something that would shape Ebola outbreaks again and again in the decades to come: healthcare amplification.

The hospital was functioning under severe resource limitations. Supplies were scarce. Sterilization capacity was limited. Disposable equipment was not consistently available.

Needles and syringes often had to be reused. And once Ebola entered that environment, the healthcare setting itself became part of the transmission chain. Patients infected healthcare workers. Healthcare workers unknowingly infected additional patients. Families caring for loved ones became exposed. Funeral preparation created further opportunities for transmission. The virus moved through proximity, caregiving, and infrastructure strain.

By the time investigators began piecing together the outbreak, hundreds of people had already died. The virus itself was eventually identified as a previously unknown member of a viral family called the filoviruses — named for their long, filament-like appearance under electron microscopy.

And the newly identified virus needed a name. Researchers chose “Ebola,” after a nearby river, partly because they wanted to avoid permanently associating the disease with Yambuku itself.

What’s interesting is that even in those earliest outbreaks, Ebola was already teaching the world an important lesson: pathogens do not spread in isolation. They move through systems. Through hospitals. Through caregiving practices. Through infrastructure limitations. Through human behavior and human necessity.

And even early on, it became clear that “Ebola” was not just one singular virus. Over time, scientists identified multiple species within the genus. Zaire ebolavirus, which would become associated with some of the deadliest outbreaks. Sudan ebolavirus. Bundibugyo ebolavirus. Taï Forest ebolavirus. And Reston virus — a species discovered later in monkeys exported to the United States that caused alarm because it appeared capable of infecting humans, but did not cause known human disease. Reston also expanded the sense that filoviruses were not confined to one familiar geography or one predictable pattern.

And to understand why this virus could become so devastating once it entered vulnerable systems, we need to zoom down to the virus itself.

PART II — A Virus Wrapped in Us

Electron micrograph of Zaire ebolavirus (1976), created by Frederick A. Murphy, D.V.M., Ph.D., at the U.S. CDC. Diagnostic specimen in cell culture, approximately 160,000× magnification. Image originally produced October 31, 1976. Public domain U.S. government image.

Up close, Ebola doesn’t look like the tidy little space probes you see in textbook drawings. It looks more like a piece of unraveled thread — long, filamentous, almost improvised-looking. In fact, the entire viral family, the filoviruses, gets its name from that appearance. “Filo” comes from the Latin word for thread.

And despite becoming one of the most feared pathogens on Earth, Ebola is biologically pretty minimal: a single strand of RNA carrying instructions for making more virus. But because that genetic material can’t be read directly by our cells, Ebola has to bring its own RNA-dependent RNA polymerase with it to start the replicatio process.

Once inside a host cell, the virus hijacks the other cell machinery it needs to copy itself. New viral particles assemble inside the cell. And then Ebola does something all enveloped viruses do: it steals from us.

As new virus particles push outward from the infected cell, they wrap themselves in pieces of the cell membrane itself. So every Ebola virion leaves the cell coated in material that originally belonged to us. That stolen outer layer — the viral envelope — helps the virus infect new cells and protects the machinery inside.

But it also creates a weakness. Lipid membranes are fragile. Soap, alcohol, bleach, drying, heat, and disinfectants can all damage or destroy them. So one of Ebola’s greatest advantages inside the body becomes one of its vulnerabilities outside it.

That’s why Ebola spreads best through direct exposure to wet infectious material — blood, vomit, diarrhea, and other bodily fluids associated with severe illness.

And once Ebola enters human systems, the biology of the virus collides with something much larger: healthcare infrastructure, caregiving, fear, and human proximity.

To understand why Ebola became so devastating in some outbreaks, you also have to understand what happens after infection begins. Inside the body.

PART III — Inside the Body

Ebola does not begin dramatically. Symptoms usually appear 2 to 21 days after exposure, most often around 8 to 10 days. It starts with the kind of fever you could easily mistake for dozens of other illnesses: fatigue, headache, muscle aches, malaise. Early Ebola virus disease often looks frustratingly nonspecific, which means patients and clinicians may not initially realize what they’re dealing with.

But beneath the surface, the virus is already moving through the body.

After entering through broken skin, mucous membranes, or contaminated fluids, Ebola infects some of the very immune cells meant to coordinate the body’s early antiviral response. Instead of stopping the virus, those cells become sites of viral replication and spread.

And one of Ebola’s most dangerous features is that it inhibits interferon, one of the body’s early immune alarm systems, giving the virus time to replicate before the immune response can fully organize itself. As viral levels rise, the problem becomes not just infection, but dysregulation. Inflammation escalates. Coagulation pathways become disrupted. Vascular stability begins to break down. Organ systems come under increasing strain.

Clinically, Ebola is very much a disease of timing. Early symptoms may seem ordinary, but as the disease progresses, the effects can become severe. Patients often develop vomiting, profuse diarrhea, abdominal pain, profound weakness, and dangerous fluid losses that can lead to dehydration, electrolyte imbalance, and shock.

Remember Jeanne, from the beginning? For people like Jeanne, this is what Ebola actually feels like — not some movie-style instant hemorrhage, but days of relentless illness and the sense that the body is gradually losing the ability to hold itself together.

Hemorrhagic symptoms can occur, including bleeding from mucosal surfaces or blood in vomit or stool, but severe bleeding is not universal. The popular image of patients simply “bleeding out” captures only part of the disease.

In many fatal cases, the greater threat is physiologic collapse. Fluid loss, inflammatory dysregulation, vascular leak, and organ failure combine into a picture that often resembles severe septic shock.

And this is where supportive care becomes critical. Intravenous fluids matter. Electrolyte replacement matters. Oxygenation matters. Blood pressure support matters. Early recognition matters.

That helps explain why mortality has differed so dramatically between settings. Ebola did not suddenly become biologically weaker in higher-resource hospitals. The physiology was the same. But the ability to support patients through the most dangerous phases of illness was profoundly different.

And there’s another layer to all of this. Because the same severe symptoms that make Ebola medically dangerous also help create the conditions that allow transmission to occur. The vomiting. The diarrhea. The caregiving demands. The need for close physical contact.

Ebola is terrifying not because it spreads effortlessly through casual human interaction, but because severe disease creates situations where exposure becomes extraordinarily difficult to avoid.

So let’s talk about transmission.

PART IV — Transmission

By the time news of an Ebola outbreak reaches most of us, we’re usually encountering it through fear first: images of healthcare workers in full protective equipment, headlines about quarantine, questions about whether the virus could “go airborne.”

Ebola spreads primarily through direct contact with infectious bodily fluids from a symptomatic person — especially blood, vomit, and diarrhea… and in certain contexts semen or breast milk. well, semen isn’t that rare in terms of persistence—it’s rare as a transmission route. But the most important words in description is symptomatic. Ebola transmission is closely tied to visible illness, with infectiousness generally increasing as patients become sicker. Unlike what we saw with some respiratory viruses during COVID, Ebola is not known for extensive presymptomatic spread by people who feel completely well.

And unfortunately, severe Ebola disease creates exactly the kinds of situations where exposure becomes difficult to avoid.

Patients become profoundly weak. They need help drinking, cleaning themselves, standing, moving, surviving.

And caregiving is intimate.

During outbreaks, family members often become infected while caring for loved ones at home. Healthcare workers become infected while treating critically ill patients. Funeral preparation can become dangerous because viral loads remain high after death and traditional burial practices may involve direct physical contact with the body.

People like Jeanne were living inside those realities — sitting beside sick relatives, cleaning them, feeding them, trying to comfort them while not fully understanding whether helping them might also kill them.

So when people say Ebola “doesn’t spread easily,” that can sound dismissive. But what it really means is that Ebola generally requires the kinds of close contact that occur during caregiving, healthcare, and severe illness. And once healthcare systems become overwhelmed, those conditions become tragically common.

That’s really the spine of this whole story: Ebola is less a story about a hyper-contagious virus and more a story about what happens when severe illness collides with fragile systems.

One of the things that terrified people during the 2014 epidemic was watching healthcare workers become infected despite wearing protective equipment. To many observers, that looked like evidence that Ebola had become airborne or unstoppable.

But that wasn’t what was happening.

Many healthcare workers were operating under extraordinary conditions: limited supplies, limited staffing, overwhelming patient volume, and extreme exhaustion. Dr. C.J. Peters once described to me how different outbreak hospitals could look compared to high-resource healthcare systems. Family members often provided food, laundry, and bedside care. Glove shortages occurred. Disposable needles were limited. Patients with early Ebola might not initially be recognized because the disease began so nonspecifically.

And Ebola care is physically brutal. Patients can lose enormous amounts of fluid through vomiting and diarrhea. Cleaning contaminated fluids creates exposure risks. Removing PPE safely requires concentration and training. The equipment itself is hot and exhausting to wear for long periods.

Protective equipment is not magic armor. It only works when staffing, supplies, sanitation, and careful technique remain functional.

One contaminated glove touching the face. One rushed removal step. One unnoticed splash. That can be enough.

Ebola does not overpower infection control. It exploits exhausted systems pushed beyond their limits.

And this is where fear often starts to outrun vocabulary. When people see respirators, isolation units, and healthcare workers getting sick, they reach for the word that feels most frightening: airborne.

But transmission is not a simple airborne-or-not-airborne binary. After COVID especially, many people hear “airborne” and think: spreads easily from person to person through shared indoor air the way measles does. But there are other kinds of transmission through the air too, including short-range droplets and aerosols generated during close patient care.

When scientists describe a virus as truly airborne in the classic sense, they usually mean it can remain infectious in tiny aerosol particles over distance and time. Measles is the classic example: someone can leave a room, and another person may become infected later simply by inhaling lingering virus in the air. That is not how Ebola behaves in real-world outbreaks.

Ebola absolutely can generate droplets and short-range aerosols during close care situations — especially around vomiting, severe illness, or certain medical procedures. And patients with severe disease can carry extraordinarily high viral loads, which is exactly why healthcare workers use extensive protective equipment.

But despite decades of outbreaks and extensive investigation, Ebola has not demonstrated sustained measles-like airborne spread.

If it did, outbreaks would look very different.

And this is part of why people sometimes ended up arguing past one another during Ebola outbreaks. One person might say, “Aerosols can occur during care,” while another hears, “This spreads through the air like measles.” Those are not the same claim.

So rather than treating “airborne” as a simple yes-or-no category, it’s more useful to focus on the actual epidemiologic pattern: Ebola spreads primarily through close contact with symptomatic patients, infectious bodily fluids, caregiving, healthcare exposure, and funeral practices.

A huge thank you to Mariella Furrer for allowing me to use these photos. Ms. Furrer is an award winning freelance photojournalist who documented the 1995 Kikwit Ebola outbreak.

One of the clearest examples of this came from the DRC In 1995, when the town of Kikwit, and surrounding villages were the epicenter of a serious Ebola outbreak between January and June. During this outbreak 317 people were infected and 245 people lost their lives. In May of that year an international team was called in to help. This team did everything they could to effectively intervene: they went house-to house searching for

patients, reviewed hospital and dispensary logs, performed retrospective contact tracing and interviewed everyone involved. One of the most interesting things to note about this outbreak is that a close look at the case definition showed that merely dying during the outbreak was as good a definition as any, with a 95% predictor of Ebola.

Investigators reconstructed chains of transmission in detail and found infections occurring in people with direct physical contact with symptomatic patients — caregivers, healthcare workers, and family members handling the sick or deceased.

But household members without direct physical contact did not become infected.

And once consistent barrier precautions were implemented — gloves, gowns, masks, eye protection, safer handling of contaminated fluids — transmission dropped dramatically.

Not futuristic biocontainment systems. Basic protection against infectious fluids.

Kikwit’s lesson was blunt: when infection-control systems hold, Ebola transmission falls. When systems fray, the virus moves into the gaps.

And one other thing about Kikwit before we move on. Some of the photographs included in this episode’s companion post were taken during the 1995 outbreak by award-winning photojournalist Mariella Furrer, whose work has documented infectious disease outbreaks and human rights crises across Africa for decades. Her images capture something that often gets lost in discussions about Ebola: the profoundly human reality inside these outbreaks. I’ve also linked her profile through the VII Foundation in the companion post if you’d like to see more of her remarkable work.

And because Ebola evokes such intense fear, people have repeatedly worried that it could “mutate airborne.” But transmission biology is constrained by complex interactions between viral structure, environmental stability, tissue tropism, infectious dose, and host biology.

There is no evidence Ebola has evolved toward efficient measles-like airborne spread.

Later outbreaks also revealed another complicated reality: viral persistence. Even after recovery, Ebola virus or viral genetic material can sometimes persist in immune-privileged sites such as semen, and rare cases of sexual transmission likely occurred.

But again, fear often expanded far beyond what the evidence supported. The overwhelming majority of Ebola transmission still occurred through the same routes seen from the beginning: caregiving, healthcare exposure, direct contact with symptomatic patients, and funeral-associated transmission.

Oh, and because this question came up repeatedly during earlier Ebola outbreaks let me preemptively clarify: there’s no evidence that household pets are major drivers of Ebola transmission in human outbreaks. Scientists have found antibodies in dogs exposed during outbreaks, suggesting exposure can occur, but dogs don't exhibit symptoms and have not been shown to play a role in sustaining human transmission.

And there’s an emotional layer to this that often gets overlooked. Survivors are not simply “vectors.” They are people recovering from catastrophic illness, grief, trauma, stigma, and loss.

Like Jeanne.

And that’s part of why outbreak communication matters so much. Because fear can distort not only how people view the virus, but how they view one another.

PART V — Fighting Back

If the first half of Ebola’s story is about devastation, the second half is about how quickly science and public health learned to fight back.

For much of Ebola’s history, outbreak response was brutally simple: identify cases, isolate patients, trace contacts, protect healthcare workers, bury the dead safely, and try to interrupt transmission chains before they outran the response.

There were no approved vaccines. No proven antiviral therapies. Supportive care was the intervention. And for decades, that shaped how the world viewed Ebola — as a virus medicine could sometimes contain, but not truly fight.

That began to change after the 2013–2016 West Africa epidemic. The scale of the outbreak forced a global realization: waiting until a crisis is already exploding before developing vaccines and therapeutics is a disastrous strategy.

So for the first time, large-scale vaccine development, therapeutic trials, and international outbreak research accelerated in parallel with an active epidemic.

And remarkably, some of it worked.

One of the biggest breakthroughs came through the Ebola vaccine now known as Ervebo, which was designed to train the immune system to recognize a key Ebola surface protein. During the West Africa epidemic, researchers tested the vaccine using a strategy called ring vaccination: identifying confirmed cases and then rapidly vaccinating their contacts and the contacts of those contacts — essentially building immunologic firebreaks around transmission chains.

The results were extraordinary. For the first time, the world had strong evidence that an Ebola vaccine could work effectively during an outbreak.

And the impact went beyond Ebola itself. The epidemic accelerated an entire framework for rapid emerging-infectious-disease response: international clinical trials, emergency vaccine deployment, and coordinated countermeasure development. In many ways, Ebola helped prepare the world for the rapid vaccine efforts we later saw during COVID.

Vaccines were only part of the story. Researchers were also trying to develop treatments for people already infected. And during later outbreaks in the Democratic Republic of the Congo, scientists managed to conduct randomized therapeutic trials under extraordinarily dangerous conditions.

Two monoclonal antibody therapies in particular — Ebanga and Inmazeb — significantly improved survival compared to older treatment approaches. That changed the landscape completely. Ebola was no longer simply a disease where clinicians could only provide supportive care and hope patients survived. There were now targeted therapies capable of improving outcomes.

And some listeners may remember that during the 2014 West Africa epidemic there was enormous interest in using convalescent blood or serum from Ebola survivors as treatment. The idea made intuitive sense: survivors had antibodies, so perhaps transferring those antibodies could help newly infected patients fight the virus. And it's effective for some viruses, like the arenavirus Junin. Junin causes Argentine hemorrhagic fever and is the virus I worked on. Convalsecent serum works well for AHF and is commonly used. But the evidence for Ebola was always far more limited than many headlines suggested. CJ and I dicussed this at length and his studies and those by others showed convalescent serum isn't effective for Ebola. He said,

"During the Kikwit episode we were harangued to give plasma or have intravenous IgG prepared and I resisted because it diluted our other efforts in a time of scarce resources.  One should also consider that the oldest strain of HIV1 was isolated by Joe McCormick from Ebola convalescent plasma drawn for potential therapy before we knew anything about that virus." 

So the bottom line is convalescent serum isn't effective for ebola and it carries significant risks in high stakes epidemic situations.

All right. So, one lesson kept appearing over and over again: timing mattered enormously for treatment.

Patients treated earlier had better outcomes. Lower viral loads correlated with survival. While delays before care increased risk.

Which reinforces something we’ve seen throughout this episode: Ebola outcomes are shaped not only by the virus itself, but by systems. Sysytems that determine: how quickly cases are recognized, whether patients can safely reach care, whether healthcare infrastructure remains functional, and whether communities trust the response enough to engage with it early.

And I should also point out that even supportive care inside Ebola treatment units is difficult. Starting IVs while wearing full protective equipment around critically ill patients with extremely high viral loads is physically and technically demanding. The interventions patients need most are often hardest to deliver during large outbreaks.

But despite those challenges, the Ebola story today is profoundly different from the one the world knew in 1976 — or even in 2014. We now have outbreak-response systems built from painful experience. That doesn’t mean the problem is solved. Major challenges remain: manufacturing capacity, cold-chain logistics, political coordination, rapid deployment, and community trust.

In fact, during the 2022 Sudan virus outbreak in Uganda, vaccine candidates arrived only after the outbreak was already fading. That’s one of the hardest realities in outbreak response: science can move extraordinarily fast and still not move fast enough.

PART VI — The Outbreak Happening Now

Even now, as I’m recording this episode, another Ebola outbreak is unfolding in Central Africa. This time involving Bundibugyo ebolavirus. The outbreak is centered in the Democratic Republic of the Congo, particularly in Ituri Province, with cases also reported in Uganda and in Kinshasa through travel-associated spread. WHO has declared it a public health emergency of international concern, and on May 18th, Africa CDC formally designated it a Public Health Emergency of Continental Security — a move that allows the organization to more aggressively coordinate response efforts, mobilize resources, and support affected countries across the region.

And the numbers have been changing rapidly. As of May 19th, the DRC and Uganda Ministries of Health reported a total of 536 suspected cases, 105 probable cases, 34 confirmed cases, and 134 deaths across the DRC and Uganda, including cases identified in Kampala. In just the previous 24 to 48 hours, officials identified 26 new confirmed cases and 143 additional suspected cases. The numbers also include two confirmed cases in Uganda, including one death, involving travelers from the DRC. At the time I’m recording this, no additional spread has been reported in Uganda. Officials warned that the true scope of transmission may still be broader than the earliest confirmed counts suggest, particularly because outbreaks like this are often recognized first through the sickest patients while surveillance is still catching up.

And analysis is bearing this out. On May 18th, researchers from Imperial College London and WHO collaborators released an early modeling analysis attempting to estimate the outbreak’s true size. Using two different approaches — one based on exported cases identified in Uganda and another based on reported deaths and likely epidemic growth rates — the team estimated that the real number of infections in the DRC may already be several hundred cases, potentially somewhere in the range of roughly 400 to 800 infections, with even higher numbers not excluded. The authors also emphasized that these estimates carry substantial uncertainty and depend heavily on incomplete surveillance data, border movement estimates, and assumptions drawn from previous Bundibugyo outbreaks. But the analysis reinforces an important reality during outbreaks like this: confirmed cases are often only the visible portion of a much larger unfolding event.

In the update on the 19th, WHO officials also acknowledged another critical concern: the outbreak appears to have been recognized relatively late. According to WHO, transmission likely spread locally in rural areas for some time before health authorities became aware of it. And this is to be expected when early symptoms are so nonspecific. In regions with limited laboratory access, difficult transportation routes, and overburdened healthcare systems, outbreaks can expand significantly before anyone realizes a filovirus is involved.

Now, one reason this outbreak immediately drew intense attention is that most existing Ebola vaccines and monoclonal antibody therapies were developed for Zaire ebolavirus, not Bundibugyo. And many of the same conditions that amplified previous Ebola outbreaks are appearing again now. Ituri is a conflict-affected region. Population movement complicates contact tracing. WHO officials warned that mining corridors, rural road networks, and cross-border movement are helping facilitate spread between affected areas. And Some deaths are reportedly occurring outside formal healthcare systems, making surveillance even harder.

There was also another challenge: diagnostics. Much of the frontline Ebola testing infrastructure in the region was optimized for Zaire ebolavirus, not Bundibugyo. That meant some suspected samples had to be shipped to the national reference laboratory in Kinshasa for confirmation. And delays like that slow isolation, contact tracing, and community warning during the exact period when early intervention matters most.

International concern has also increased because WHO officials have also confirmed deaths among healthcare workers, indicating ongoing healthcare-associated transmission — one of the classic warning signs that Ebola is amplifying through strained care systems. On May 17th, U.S. officials confirmed that an American healthcare worker exposed while caring for patients in the DRC tested positive for Bundibugyo and was being transferred to Germany for treatment alongside several high-risk contacts. Germany was selected partly because of its previous experience caring for Ebola patients in specialized isolation units. And also because the US facility is busy hosting people still isolating for possible hantavirus infection.

International health officials are also taking the outbreak seriously because the scale at declaration was already unusually large for Ebola. Public health experts warned that the outbreak may take significant time to fully contain, particularly given insecurity, population movement, and the operational difficulty of tracing transmission chains across affected regions.

On May 18, U.S. authorities also issued a Title 42 order barring entry of non-citizens who've been in the Democratic Republic of the Congo, Uganda, or South Sudan in the past 21 days. It might seem like a good idea but travel bans are tricky. They do little to address the underlying drivers of Ebola outbreaks and often do more harm. They complicate response efforts by increasing stigma toward patients, survivors, and affected communities and countries, discouraging transparent case reporting. And they end up causing people to move across borders through unofficial routes that are much harder for public health teams to monitor. And on top of that they impede access of healthcare workers and supply convoys into impacted areas.

The best approach is what has worked historically: the established public health measures to prevent travel associated spread of ebola including pre- and post-travel screening, monitoring upon arrival, 3 weeks of contact follow-up, and hospitals staged for isolation and treatment if needed.

And that approach works, because as we've talked about, Ebola is not a virus that spreads through populations the way pandemic respiratory viruses do. Its transmission patterns are fundamentally different. Unlike COVID, Ebola patients typically become severely ill relatively early in infection, which limits the kind of widespread presymptomatic community transmission that drives true pandemics. So places with robust healthcare systems, infection-control practices, laboratory networks, and trained personnel can interrupt Ebola transmission relatively quickly. Outbreaks like this are reminders that those systems should not be taken for granted. They require long-term investment and maintenance. In many ways, public health infrastructure is part of societal resilience and national security — even if we tend to notice it most clearly when it begins to fail.

The greatest danger in this outbreak is for Ituri and the surrounding communities. Where severe disease intersects with fragile systems — overwhelmed hospitals, limited resources, armed conflict, displacement, and distrust. And distrust is no small thing.

As experts who've been in the area facing previous ebola outbreaks point out, there’s another difficult layer to this story too: trust. In some communities, Ebola response efforts exist alongside long histories of under-resourced healthcare, political instability, and outside intervention. People have watched enormous international attention arrive for Ebola while malaria, measles, maternal mortality, tuberculosis, and everyday healthcare needs remain chronically neglected. That history shapes how outbreak response is perceived, undermining the very trust that is needed for outbreak control.

Before we wrap, I want to take a few listener questions. So, The Hot Zone Hotline is open.

Hot Zone Hotline

Q1: The first question is from Orestes of Alexandria  — @AlxanderOrestes on Twitter —who asks: “Ebola seems scariest to me, but it doesn’t get as much attention — why might that be?”

Answer: Ebola is terrifying because the symptoms are dramatic and the death rate can be very high in some outbreaks — sometimes 25% to over 50%. But the reason it usually doesn’t dominate global attention the way COVID did is because Ebola is actually much harder to spread. Ebola spreads through direct contact with bodily fluids from someone who is already visibly sick — blood, vomit, diarrhea, things like that. It’s not casually airborne like COVID or measles. That means outbreaks tend to burn intensely but stay more geographically contained. Another reason is that public health systems now know Ebola pretty well. We have outbreak protocols, contact tracing methods, protective equipment, rapid isolation procedures, and now even vaccines and antibody treatments that didn’t exist during earlier outbreaks. So Ebola is incredibly deadly, but it’s not very efficient at spreading between humans compared to respiratory viruses. A virus with a lower death rate but much easier transmission can actually kill far more people globally — which is exactly what happened with COVID.

Q2: Next question comes from Kathryn H who asked: “Why does Ebola keep coming back?”

Answer: Because Ebola isn’t a human virus that we can eliminate once and be done with. Humans are spillover hosts. The virus persists in animal reservoirs — and it looks like it's certain bat species for at least some filoviruses — where it continues circulating largely outside human awareness. That means even if one outbreak is completely controlled, the virus itself has not disappeared from nature. New spillover events can still occur through wildlife exposure, hunting, environmental disruption, or human movement into previously less-disturbed ecosystems.

Most spillover events probably never become major outbreaks. Some may involve only a single infection or a small cluster. But occasionally, the conditions align in ways that allow amplification. And that’s really the key. Ebola outbreaks become dangerous when severe disease collides with delayed recognition, under-resourced hospitals, overwhelmed healthcare workers, armed conflict, displacement, limited laboratory access, and distrust of authorities or responders.

So Ebola keeps coming back partly because spillover keeps happening — and partly because the conditions that allow outbreaks to amplify still exist.

And, Scientists in the DRC and Uganda have also now released the first complete genome sequences from the current outbreak. And early phylogenetic analysis suggests these viruses do not closely match previously sequenced Bundibugyo outbreak strains from 2007 or 2012. That suggests that this outbreak was from a new spillover event from wildlife into humans, rather than continued hidden human transmission from earlier outbreaks.

Q3: The Third question is from Mark Emalfarb — @Emalfarb — who asked: “Why isn’t manufacturing capacity the #1 story in global health if a future virus could kill 10–30%?”

Answer: This is actually a really important point. During COVID, scientists developed vaccines and antibody treatments at record speed. The bottleneck wasn’t always the science — it was manufacturing billions of doses fast enough. If we ever faced a virus that spread like COVID but killed 10% or more of infected people, manufacturing speed would become absolutely critical. Every month of delay could mean millions of deaths. That’s why there’s so much interest now in faster vaccine platforms like mRNA and next-generation antibody manufacturing. Traditional vaccine systems can take months to scale up. Newer platforms can potentially respond in days or weeks. But there’s also an important reality check here: viruses that are extremely deadly often spread less efficiently because they incapacitate or kill hosts quickly. The nightmare scenario is a pathogen that combines high transmissibility with high lethality — and thankfully, nature doesn’t produce that combination very often. Still, the COVID pandemic exposed how fragile global manufacturing and supply chains really are. So a lot of experts now argue that vaccine and therapeutic manufacturing capacity should be treated almost like national defense infrastructure. And if we want those platforms ready before the next crisis, we need leadership that treats vaccine and therapeutic manufacturing like critical infrastructure, not an afterthought.

And I think that’s actually a good place to leave the Hot Zone Hotline for tonight.

Because so many of the questions people ask about Ebola eventually circle back to the same themes: fear, transmission, uncertainty, and the tension between what the virus actually does and what people imagine it might do.

Closing

Ebola became one of the most feared pathogens on Earth long before most people understood how it actually worked. And in some ways, that’s understandable.

It is a terrifying disease. Not because it spreads invisibly across continents with impossible efficiency. Not because it’s unstoppable. But because severe disease is terrifying. Because watching healthcare workers become infected is terrifying. Because outbreaks reveal how fragile systems can become under pressure. And because Ebola forces people into one of the hardest situations in infectious disease: caring for someone you love while also fearing contact with them.

That’s the emotional center of Ebola outbreaks. Caregiving. Again and again, Ebola spreads through acts of proximity and responsibility: family members cleaning the sick, nurses trying to keep patients alive, exhausted healthcare workers continuing to show up anyway, communities trying to bury their dead with dignity while also trying to survive.

And when diseases become mythology, we sometimes lose sight of the humans inside the story. The survivors like Jeanne. The healthcare workers. The researchers trying to understand a virus much of the world encountered primarily through fear. The communities navigating grief, stigma, isolation, and uncertainty all at once.

What began in 1976 as an unidentified hemorrhagic outbreak has become decades of accumulated knowledge about outbreak response, supportive care, vaccines, therapeutics, and the ecology of emerging disease. Not all at once. Not cleanly. And not without mistakes. But gradually.

But as this outbreak unfolds in Central Africa, the tragedy will continue...there are, and will continue to be, new Jeannes — people sitting beside sick relatives, weighing the risk of touching someone they love against the horror of not touching them at all.

Thanks for being here. I’ll continue providing updates on both the hantavirus and Ebola outbreaks in my weekly newsletter, Field Notes, which comes out Wednesday mornings and is free to subscribe to at Infectiousdose.com. That’s also where you’ll find companion blog posts for every episode, with transcripts and full citations.

And next week on Outbreak After Dark, we’re heading into true crime territory with the case that brought forensic virology into the courtroom for the first time.

And because I don’t want to delay that episode, if there are major developments in either outbreak — or enough new listener questions come in — I’ll drop a shorter update episode separately. You can send questions anytime to infectiousdose@gmail.com or leave them in the comments on posts over on Twitter, Bluesky, or Instagram.

ANNOTATED CITATIONS

PDFs are provided for paywalled hyperlinks

UNICEF. An Ebola survivor story. 28 May 2021. UNICEF Democratic Republic of the Congo. https://www.unicef.org/drcongo/en/stories/an-ebola-survivor-story

➡️This is a human-interest survivor narrative rather than a scientific publication, but it can be extremely valuable for illustrating the lived experience of Ebola infection, stigma, recovery, and survivor reintegration. It helps contextualize the emotional and social dimensions of outbreaks that are often missing from technical medical literature.

Report of a WHO/International Study Team. 1978. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ. https://pmc.ncbi.nlm.nih.gov/articles/PMC2395561/

➡️This is one of the original foundational Ebola outbreak reports documenting the first recognized Sudan virus epidemic in Nzara and Maridi, Sudan (now South Sudan). The paper established many of the earliest observations about Ebola transmission, nosocomial spread through reused needles, clinical presentation, and case fatality patterns, making it historically indispensable for understanding how Ebola first emerged into medical awareness.

Report of an International Commission. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. https://pmc.ncbi.nlm.nih.gov/articles/PMC2395567/

➡️The companion report to the Sudan outbreak paper, this landmark investigation documented the Yambuku outbreak caused by Zaire ebolavirus, the deadliest Ebola species known. It is especially important for tracing how unsafe injection practices, hospital amplification, and funeral transmission fueled explosive spread, while also providing some of the earliest detailed descriptions of Ebola pathology and epidemiology.

Feldmann, H., Sprecher, A., & Geisbert, T. W. (2020). Ebola. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMra1901594

➡️Great single-paper overview. It concisely covers Ebola history, viral structure, pathogenesis, transmission dynamics, outbreak control, supportive care, vaccines, monoclonal antibody therapies, and survivor syndromes, while also distinguishing among ebolavirus species and their differing lethality.

Nicastri, E., Kobinger, G., Vairo, F., et al. (2019). Ebola virus disease: epidemiology, clinical features, management, and prevention. Infectious Disease Clinics of North America. https://www.sciencedirect.com/science/article/abs/pii/S0891552019300649?via%3Dihub

Nicastri 2019 Ebola Virus Disease Epidemiology Clinical Features Management and Prevention.

Download • 1.10MB

➡️A clinically oriented review that excels at explaining how Ebola actually presents and spreads in real outbreaks. Particularly useful for discussing healthcare worker risk, infection prevention protocols, contact tracing, and the limitations of then-current vaccines and therapeutics outside Zaire ebolavirus..

Feldmann, H., & Geisbert, T. W. (2011). Ebola haemorrhagic fever. The Lancet. https://www.thelancet.com/article/S0140-6736(10)60667-8/fulltext

➡️One of the classic foundational Ebola reviews written by two of the field’s most respected researchers. It goes deeply into viral entry, immune evasion, cytokine dysregulation, vascular injury, and why Ebola causes such catastrophic systemic disease, while also summarizing early therapeutic and vaccine strategies before the West African epidemic transformed the field.

Jacob, S. T., Crozier, I., Fischer, W. A., et al. (2020). Ebola virus disease. Nature Reviews Disease Primers. https://www.nature.com/articles/s41572-020-0147-3

Jacob 2020 Ebola virus disease.pdf

Download PDF • 5.54MB

➡️Arguably the most comprehensive modern synthesis of Ebola biology and medicine. It integrates molecular virology, ecology, epidemiology, transmission, pathology, diagnostics, intensive care, survivor complications, sexual transmission persistence, and public health response into a single highly readable review with excellent figures and outbreak context.

Taki E, et al. 2023. Ebanga™: The most recent FDA-approved drug for treating Ebola. Front Pharmacol. https://pmc.ncbi.nlm.nih.gov/articles/PMC10032372/

➡️This review focuses on ansuvimab (Ebanga), one of the monoclonal antibody therapies shown to improve survival during the PALM trial in the DRC. The paper explains the drug’s mechanism—targeting the Ebola glycoprotein to block viral entry—and situates Ebanga within the broader evolution of Ebola therapeutics from experimental antibodies to FDA-approved treatment.

Rayaprolu V, et al. 2023. A Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host & Microbe. https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(23)00022-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1931312823000227%3Fshowall%3Dtrue

➡️This structurally focused paper examines how the three monoclonal antibodies in Inmazeb bind Ebola virus glycoprotein and why combining multiple antibodies reduces the chance of viral escape mutations. It is particularly valuable for explaining the modern logic of antibody “cocktails” and how structural biology guides antiviral drug design against rapidly evolving viruses.

Rasmussen, A.L., et al. 2014. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science. https://doi.org/10.1126/science.1259595 

➡️This landmark paper demonstrated that host genetics strongly influence Ebola disease severity and survival. Using genetically diverse mouse models, the researchers reproduced a spectrum of outcomes resembling human Ebola infection—from resistance to lethal hemorrhagic disease—providing major insights into why Ebola affects individuals so differently and highlighting the importance of immune regulation in pathogenesis.

Khan, et al, for the Commission de Lutte contre les Epidémies à Kikwit. 1999. The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995, The Journal of Infectious Diseases. https://academic.oup.com/jid/article-abstract/179/Supplement_1/S76/882543?redirectedFrom=fulltext&login=false

➡️This is one of the most important outbreak reconstruction papers from the pre-genomics era. It carefully analyzes the 1995 Kikwit epidemic, emphasizing transmission chains, healthcare-associated spread, quarantine measures, burial practices, and public health interventions that became foundational for later Ebola outbreak response strategies.

Di Paola, N., Sanchez-Lockhart, M., Zeng, X., et al. (2020). Viral genomics in Ebola virus research. Nature Reviews Microbiology, 18, 365–378. https://www.nature.com/articles/s41579-020-0354-7

Di Paola 2020 Viral genomics in Ebola virus research.pdf

Download PDF • 2.79MB

➡️An outstanding review for understanding how genome sequencing transformed Ebola outbreak investigations. It explains how researchers track spillover events, transmission chains, viral evolution, species divergence, and persistence in survivors, especially during the 2014–2016 West African epidemic and later DRC outbreaks.

Jain, S., Khaiboullina, S., Martynova, E., et al. (2023). Epidemiology of ebolaviruses from an etiological perspective. Pathogens. https://www.mdpi.com/2076-0817/12/2/248

➡️One of the best concise reviews focused specifically on comparing ebolavirus species. It discusses Zaire, Sudan, Bundibugyo, Taï Forest, Reston, and Bombali viruses individually, including geography, case fatality rates, host ecology, known outbreaks, and the critical distinction that Reston infects humans without causing recognized disease.

Marzi, A., & Feldmann, H. (2024). Filovirus vaccines as a response paradigm for emerging infectious diseases. npj Vaccines. https://www.nature.com/articles/s41541-024-00985-y

➡️A current state-of-the-field vaccine review from two leading filovirus researchers. It explains the development of rVSV-ZEBOV and adenoviral vaccine platforms, discusses durability and correlates of protection, and highlights a key unresolved issue: most approved vaccines are optimized for Zaire ebolavirus and may not fully protect against Sudan or Bundibugyo viruses.

Towner, J. S., Sealy, T. K., Khristova, M. L., et al. (2008). Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000212

➡️The definitive discovery paper for Bundibugyo ebolavirus (BDBV). It documents the 2007 Ugandan outbreak, demonstrates that the virus was genetically distinct from previously known Ebola species, and established Bundibugyo as a new species within the genus Ebolavirus.

MacNeil, A., Farnon, E. C., Morgan, O. W., et al. (2011). Filovirus outbreak detection and surveillance: lessons from Bundibugyo. Journal of Infectious Diseases. https://academic.oup.com/jid/article-abstract/204/suppl_3/S761/2192185?redirectedFrom=fulltext

MacNeil_Filovirus Outbreak Detection and Surveillance Lessons From Bundibugyo.pdf

Download PDF • 253KB

➡️An important epidemiological paper on the Bundibugyo outbreak response. It details how delayed recognition, surveillance limitations, local healthcare infrastructure, and case tracking affected outbreak control, making it very useful for discussing the realities of Ebola response in rural East/Central Africa.

Mulangu, S., Dodd, L. E., Davey, R. T., Jr., et al. (2019). A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1910993

➡️Landmark PALM trial that fundamentally changed Ebola treatment. Conducted during the 2018–2020 DRC outbreak, it demonstrated that monoclonal antibody therapies REGN-EB3 and mAb114 significantly improved survival compared with older treatments, especially when patients received therapy early.

Henao-Restrepo, A. M., Camacho, A., Longini, I. M., et al. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease. The Lancet.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32621-6/fulltext

➡️The landmark “ring vaccination” study from Guinea that provided the strongest evidence that the rVSV-ZEBOV vaccine could stop Ebola transmission in outbreak settings. This paper is central for discussing how vaccination strategies evolved from individual protection to epidemic containment tools.

WHO News. Dec 9, 2022. Ebola trial candidate vaccines arrive in Uganda in record 79 days after outbreak declared. https://www.who.int/news/item/09-12-2022-ebola-trial-candidate-vaccines-arrive-in-uganda-in-record-79-days-after-outbreak-declared

➡️This WHO news release documents the unusually rapid international response to the 2022 Sudan virus outbreak in Uganda. It highlights how lessons from the West African and DRC epidemics accelerated vaccine trial deployment infrastructure and also underscores a major issue in Ebola preparedness: licensed vaccines existed for Zaire ebolavirus, but not yet for Sudan virus.

Munyeku-Bazitama, Y., Edidi-Atani, F., & Takada, A. (2024). Non-Ebola filoviruses: potential threats to global health security. Viruses. https://www.mdpi.com/1999-4915/16/8/1179

➡️Valuable modern review expanding beyond the better-known Zaire outbreaks to the broader filovirus landscape. It discusses lesser-known species such as Bombali and Reston viruses, reservoir ecology in bats, zoonotic spillover risk, and why future filovirus emergence may not resemble previous Ebola epidemics.

Delia A. Enria, AnaM. Briggiler, Zaida Sánchez. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Research. https://www.sciencedirect.com/science/article/abs/pii/S0166354207004330?via%3Dihub

Enria 2007 Treatment of Argentine hemorrhagic fever.pdf

Download PDF • 553KB

➡️This review focuses on Argentine hemorrhagic fever caused by Junín virus, another viral hemorrhagic fever with important parallels to Ebola. It is especially notable for discussing the successful use of immune plasma from survivors.

Oswald WB, Geisbert TW, Davis KJ, Geisbert JB,Sullivan NJ, et al. (2007). Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys. PLoS Pathog. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.0030009

➡️This influential study challenged the assumption that simply generating neutralizing antibodies would be sufficient to stop Ebola infection. Using nonhuman primates, the authors showed that antibodies capable of neutralizing Ebola virus in vitro did not necessarily protect animals in vivo, helping reshape the field’s understanding of protective immunity and guiding later monoclonal antibody development toward broader immune mechanisms.

P. B. Jahrling, T. W. Geisbert, J. B. Geisbert, J. R. Swearengen, M. Bray, N. K. Jaax, J. W. Huggins, J. W. LeDuc, C. J. Peters. 1999. Evaluation of Immune Globulin and Recombinant Interferon-α2b for Treatment of Experimental Ebola Virus Infections. The Journal of Infectious Diseases. https://doi.org/10.1086/514310

Jahrling et al Peters 1999 Evaluation of Immune Globulin and Recombinant Interferon-α2b fo.

Download • 864KB

➡️A foundational pre-2014 therapeutic study testing early immune-based Ebola treatments in experimental models. The paper found that passive immune globulin and interferon therapy offered limited protection, illustrating how difficult Ebola treatment development was before the advent of highly optimized monoclonal antibody cocktails like REGN-EB3 and mAb114.

CDC. May, 2026. Ebola Disease Ebola Disease: Current Situation. https://www.cdc.gov/ebola/situation-summary/index.html

➡️This CDC page provides updates on the May 2026 Ebola Outbreak in the DRC.